Relationship and Central Mechanism Between Diabetes and Cognitive Impairment Based on Simultaneous EEG-fMRI Approach and Peripheral Neuropathology Biomarkers Assay

Sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

About this trial

Last updated 4 years ago

Study ID

2022-LCYJ-MS-03

Status

Unknown

Type

Observational

Placebo

Accepting

40 to 75 Years

All Sexes

Trial Timing

Ended 9 months ago

What is this trial about?

This is a cross-sectional and longitudinal study to investigate the relationship and central mechanism between type 2 diabetes and cognitive impairment based on the simultaneous EEG-fMRI approach and peripheral neuropathology biomarkers assay.

What are the participation requirements?

Inclusion Criteria

* Aged 40-75 years

* Right handedness

* Possessed over 6-year education

* Provision of informed consent prior to any study specific procedures

Exclusion Criteria

* Control participants would be excluded if they had a fasting blood glucose level >7.0 mmol/L; glucose level> 7.8 mmol/L after oral glucose tolerance test (OGTT); HbA1c>5.7%

* Control participants would be excluded if they had a Montreal Cognitive Assessment (MoCA, Beijing edition) score of < 26

* History of other dementia-related neurological or psychiatric disorders, including psychotic developmental disorders, mania, depression, and schizophrenia

* Central neural system diseases, including traumatic brain injury, intracranial hemorrhage, and acute cerebral infarction

* Acute complications of diabetes, including diabetic ketoacidosis, hyperglycemic hyperosmolar state, and hypoglycemic coma

* Complicated with severe impairment of liver, kidney or heart function

* Metal implants, unable to complete the MR scanning

* Pregnant or lactating women